Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral favipiravir for delayed SARS-CoV-2 viral RNA clearance
ChiCTR2000033491Phase 4Completed
- Sponsor
- Huoshenshan Hospital
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of favipiravir in coronavirus disease 2019 (COVID-19), sponsored by Huoshenshan Hospital. Primary endpoint: SARS-CoV-2 viral RNA PCR test. Started Mar 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000033491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033491.